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Abstract
Background: In England, Public Health England conducts enhanced surveillance of invasive meningococcal disease
(IMD). The continuing decline in reported IMD cases has raised concerns that the MRU may be underestimating
true IMD incidence.
Methods: We linked five national datasets to estimate disease burden over five years, including PHE Meningococcal
Reference Unit (MRU) confirmations, hospital episode statistics (HES), electronic reports of significant infections by
National Health Service (NHS) Hospitals, death registrations and private laboratory reports.
Results: During 2007–11, MRU confirmed 5115 IMD cases and 4275 (84 %) matched to HES, including 3935 (92 %)
with A39* (meningococcal disease) and 340 (8 %) with G00* (bacterial meningo-encephalitis) ICD-10 codes. An
additional 2792 hospitalised cases with an A39* code were identified in HES. Of these, 1465 (52 %) matched to one
of 53,806 samples tested PCR-negative for IMD by MRU and only 73 of the remaining 1327 hospitalised A39* cases
were confirmed locally or by a private laboratory. The characteristics of hospitalised cases without laboratory
confirmation were similar to PCR-negative than PCR-positive IMD cases.
Conclusions: Interrogation of multiple national data sources identified very few laboratory confirmations in
addition to the MRU-confirmed cases. The large number of unconfirmed and PCR-negative cases in HES suggests
increased awareness among clinicians with low thresholds for hospitalising patients with suspected IMD.
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Background
Invasive meningococcal disease (IMD) is associated with
significant case fatality and long-term morbidity despite
availability of effective antibiotics and intensive care sup-
port in industrialised countries [1, 2]. Efforts to control
the disease have, therefore, focussed on prevention, pri-
marily through vaccination [3]. Most cases of IMD are
caused by one of six meningococcal capsular groups,
which are characterised by their unique polysaccharide
capsule (A, B, C, W, X or Y) [4]. In the United Kingdom,
meningococcal group C (MenC) is rare because of a suc-
cessful national immunisation programme and group B
(MenB) is responsible for most IMD cases across all age
groups [5].
In England, national surveillance of laboratory-
confirmed IMD is conducted by Public Health England
(PHE), through the Meningococcal Reference Unit
(MRU), which provides a national service for species
confirmation, grouping, typing, subtyping and anti-
microbial susceptibility testing of all invasive Neisseria
meningitidis isolates. The MRU also provides free non-
culture PCR confirmation of meningococcal diagnosis
(including genogroup and genosubtype analysis) for clin-
ical specimens that are routinely submitted by National
Health Service (NHS) hospitals in England [5]. We have
recently highlighted the added value of the PCR-testing
service because of its high sensitivity and specificity,
which has proved invaluable in achieving high case as-
certainment rates for IMD surveillance [6]. However,
whilst the current surveillance provides important infor-
mation on the epidemiology of IMD and trends over
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time, it may underestimate the true burden of disease if
clinical specimens are not submitted to the MRU or if
hospitals submit their clinical isolates to private labora-
tories that provide a similar service. Cases that are diag-
nosed clinically without laboratory-confirmation, too,
would not be included in the current surveillance. This
may be more important for the less prevalent meningo-
coccal capsular groups, which have more varied clinical
presentations and often affect older adults with co-
morbidities [7]. Likewise, meningitis cases may be
missed if lumbar punctures are not performed [8].
In order to define the true burden of IMD, it is im-
portant to evaluate routine surveillance against alternate
data sources. Accurate data form an essential compo-
nent for modelling the potential impact (including cost-
effectiveness) of any new vaccine which, in turn, can be
used to inform national vaccination policy. The use of
existing national datasets as a means of undertaking
health research and improving public health monitoring
offers exciting opportunities to undertake very large
scale studies at very low cost. This study aimed to inte-
grate epidemiological, clinical, microbiological and out-
come data using multiple national datasets to assess the
burden of IMD in England over a five-year period.
Methods
PHE conducts enhanced surveillance of vaccine-
preventable infections in England. For this study, five in-
dependent national datasets covering the five-year
period during 2007–2011 were de-duplicated prior to
linkage (Table 1). In addition to data collected through
provision of a national reference laboratory service, PHE
also routinely receives electronic notifications of clinic-
ally significant isolates by NHS laboratories through
LabBase2 and reports of PCR-confirmed cases from pri-
vate laboratories that support microbiology services for
NHS hospitals. PHE also has access to Hospital Episode
Statistics (HES), an online database containing electronic
records of patients admitted to NHS hospitals, and re-
ceives annual electronic reports of all death registrations
in England from the Office for National Statistics (ONS).
PHE has been granted access to these data, through Regu-
lation 3 of The Health Service (Control of Patient Infor-
mation) Regulations 2002 (http://www.legislation.gov.uk/
uksi/2002/1438/regulation/3/made) in order to fulfil its
legal responsibility to monitor the impact, safety and
effectiveness of the national immunisation programmes.
Prior to linkage, the Hospital Episode Statistics (HES)
spells and episodes were converted to individual admis-
sions. The electronic Patient Demographic Service (PDS)
was used to maximise the number of cases with an NHS
number using other identifiable data for individual cases.
PDS is a national electronic database of NHS patient
demographic details that allows healthcare staff to
identify patients quickly and accurately (http://system-
s.hscic.gov.uk/demographics/pds). For all interrogated
datasets, cases linked by NHS number were verified
using the other linkage parameters (date of birth, sex,
etc.) before being considered exact matches. The
remaining unmatched cases where then matched using
date of birth, gender and postcode, followed by different
combinations of approximate date of birth, gender, re-
gion and approximate time of infection. All cases were
then linked with the ONS death registration records to
identify any extra cases not reported in the MRU or
HES dataset, to ensure more complete outcomes for
linked cases and to ascertain cause of death. Because
LabBase2 and the private laboratory provided very few
additional laboratory-confirmed cases to the total MRU-
confirmed cases, these two data sources were interro-
gated at the end to identify any HES cases that might
have been confirmed by laboratories other than the
MRU. For LabBase2, individual clinical specimen re-
cords with an organism code for NEISSERIA MENINGI-
TIDIS and with a specimen date in the study period
were extracted, de-duplicated and linked to the MRU
database. Linkage was done using NHS Number, patient
surname, forename, date of birth, date of specimen,
postcode and reporting laboratory. Any remaining epi-
sodes that did not link to the MRU database were then
linked to the HES database. Case fatality ratio (CFR) re-
fers to a fatal outcome within 30 days of a positive la-
boratory test and, where this date was not available, then
the date of admission was used as a proxy. Patients with
the same postcode for place of residence and place of
death were considered to have died at home.
Results
MRU dataset
During 2007–11, the MRU confirmed 5115 IMD cases
and 53,806 blood/CSF samples tested PCR-negative for
IMD. Annual MRU-confirmed cases (and negative PCR-
tests) were 1213 (10,112), 1170 (10,892), 963 (10,939),
885 (10,884) and 884 (10,979) for the 5-year period.
Capsular group data were available for 4,963 cases and
included MenB (n = 4435, 89 %), MenY (n = 278, 6 %),
MenW (n = 124, 3 %), MenC (n = 115, 2 %) and other
capsular groups (n = 11).
HES dataset
During the same 5-year period, 62,183 total episodes
with the selected ICD-10 codes for meningococcal dis-
ease (A39*) or any cause of bacterial meningo-
encephalitis (G00*) were extracted, resulting in 61,867
episodes after de-duplication, equivalent to 42,558 ad-
missions for 31,004 individuals. Of these, 8470 (20 %)
admissions and 6727 (22 %) individuals had an A39*
ICD10 code.
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Linking MRU cases to HES
MRU+/HESA39+ cases
Of the 5115 MRU-confirmed cases, 4275 (84 %) matched
exactly to a HES admission, including 3935 (92 %)
matched to an A39* (meningococcal disease) diagnosis
and 340 (8 %) to a G00* (bacterial meningo-encephalitis)
diagnosis. The age distribution indicated a higher propor-
tion of cases in young children with a peak among 1–4
year-olds and smaller peaks among 15–24 and 45–64 year-
olds (Fig. 1a). Case fatality for this group was 4.0 % overall,
with CFR remaining <5 % for all age-groups except
≥65 year-olds, where it was significantly higher (Fig. 1b).
MRU+/HESA39- cases (n = 840)
Comparison of the 3935 MRU+/HESA39+ cases with
the 840 MRU-confirmed cases that did not match to
HES (i.e. MRU+/HESA39-) indicated that children and
young adults aged <25 years (81 % vs. 69 %), and those
with MenB disease (89 % vs. 77 %), were more likely to be
recorded as IMD in HES (Fig. 2). In a logistic regression
model with MRU+/HESA39+ and MRU+/HESA39- as
outcome variables (0/1), failure to link with a HESA39*
code was independently associated with increasing age in
years (aOR 1.008, 95 % CI 1.004-1.011; P < 0.001), non-
menB cases (2.0; 95 % CI, 1.6-2.5; P < 0.001) and fatal
cases (aOR 3.9, 95 % CI 3.0-5.0; P < 0.001).
Upon further analysis of the 840 MRU+/HESA39-
cases, 555 had an NHS number recorded. These
cases were re-interrogated with the HES database to
ascertain their discharge diagnoses. Of these, 456 had a
HES admission between March 2006 and April 2012,
including 345 (62 %) within 30 days of the MRU-positive
test. Most MRU-confirmed cases could be linked to an
infection-related HES admission around the time of
sample receipt at the MRU (Table 2).
Notably, the overall CFR for the MRU+/HESA39- co-
hort was higher than would be expected for IMD
(14.5 %), especially among those with an NHS number
recorded but did not link to a HES admission (NHS
number+/Unlinked) (Table 3). Analysing the timing of
MRU-confirmation of IMD and date of death revealed
that nearly all confirmations within 30 days of death oc-
curred on the day or in the days after the patient died
(Additional file 1: Figure S1), suggesting that these pa-
tients had not been admitted to hospital and had died ei-
ther in the Emergency Department or outside the
hospital. This was generally true for all subgroups within
the MRU+/HESA39- cohort and interrogation of the
death registration records identified at least 19 patients
who had died at home. Interestingly, although the HES
ICD-10 codes for the MRU+/HESA39- cohort ranged
between infection-related, another-pathogen-recorded,
and non-infection codes, the death registration records
for nearly all of the 122 fatal cases specifically docu-
mented IMD as the cause of death, with only six record-
ing a non-specific infection-related death (Table 3).
Table 1 Summary and characteristics of datasets used for the linkage study to estimate the total burden of invasive meningococcal
disease (IMD) in England over a five-year period (2007–11)
PHE MRU laboratory-confirmed
IMD cases
PHE MRU provides a national service for meningococcal species confirmation and molecular characterisation
of invasive clinical isolates as well as a free national polymerase chain reaction (PCR) service to detect
meningococcal DNA in clinical specimens from National Health Service (NHS) hospital laboratories throughout
England. The MRU dataset maintains a record of all laboratory-confirmed cases, including NHS number, patient first
name, surname, date of birth, referring hospital, sample source (blood, CSF, etc.), meningococcal capsular group,
molecular analysis and date of death (if died).
Office for National Statistics
death registrations (ONS)
The Office for National Statistics (ONS) (www.statistics.gov.uk) provides PHE a record of annual death registrations
in England for public health surveillance purposes and routinely converts the text within death certificates into
ICD-10 codes. Data contained in the ONS database includes NHS number, patient first name, surname, date of
birth, sex, place of residence, date of death, place of death and cause of death in free text and ICD-10 codes.
PHE LabBase2 PHE manages a central database (LabBase2) that collects routine electronic laboratory reports of clinically
significant isolates reported voluntarily by NHS hospital laboratories in England. Data contained within
LabBase2 include NHS number, patient first name, surname, date of birth, sex, reporting hospital, date of
specimen, pathogen and antimicrobial susceptibility profile.
Private laboratory reports Although MRU processes nearly all meningococcal isolates and clinical specimens for PCR-testing from
NHS hospital laboratories in England, a few hospitals send some of their clinical specimens to one major
private medical micro-pathology laboratory for PCR-testing. This laboratory routinely reports all
PCR-positive IMD confirmations to PHE.
Hospital Episode Statistics (HES) This database is managed by the Health and Social Care Information Centre and contains details of all
admissions to NHS hospital trusts in England (~11 million episodes/year). HES contains a wide range of
information, including NHS number, date of birth, sex, place of residence, ethnicity, admitting hospital,
underlying medical conditions, timing and duration of inpatient-stay, reasons for admission and outcome
at discharge. Potential episodes associated with a meningococcal infection were extracted by searching for
any meningococcal (A39*), meningococcal-related (M010A, meningococcal arthritis; M030A; post-meningococcal
arthritis) or infectious meningo-encephalitis (G00*) ICD-10 code in either the primary or the 19 secondary
diagnostic codes. This is in contrast to published HES data that only report diagnoses in the primary
diagnostic column. Data for linkage to MRU cases included NHS number, sex, DOB and postcode.
Ladhani et al. BMC Infectious Diseases  (2015) 15:551 Page 3 of 10
HES cases that did not link to MRU-confirmed cases
Since only 3935 (58 %) of the 6727 HES cases with an
A39* ICD-10 code (meningococcal disease) linked
with the MRU-confirmed cases, there were, therefore,
an additional 2792 (42 %) HES A39*cases that were
not confirmed by the MRU. These additional cases
were interrogated against 53,806 MRU PCR-negative
reports and 1465 (52 %) matched to a PCR-negative
result (HES+/MRU- cases). These cases, therefore,
represent a cohort that had a diagnosis code for IMD
in HES even though the patient had been tested by
the MRU as PCR-negative. The interval between the
date of hospital admission and the date when the PCR-
test sample was received at the MRU was similar for MRU
+/HESA39+ and HES+/MRU- cases (Fig. 3), suggesting
that delay in PCR-testing from the date of admission was
unlikely to explain the PCR-negative result.
Additionally, there were a further 1327 HESonly cases
with an A39* ICD-10 code did not match to MRU-
positive or MRU-negative cases. Interrogation of these
cases with LabBase2 and private microbiology laboratory
reports identified 43 and 30 additional cases that linked
to the HESonly cases, respectively; these were, therefore,
additional laboratory-confirmed IMD cases that had
not been included among the MRU-confirmed cases.
Assuming no duplication between these two additional
data sources, this would suggest that the remaining
(1327-43-30=) 1254 cases, equivalent to 251 annual
cases, had no evidence of laboratory-confirmation for
IMD, indicating that these cases were most likely diag-
nosed clinically . The age-distribution of HESonly cases
(Fig. 1a) shows a predominance of cases in infants, tod-
dlers and older children (the age groups considered to
be at highest risk of IMD), with few cases in adults.
Fig 1 Age distribution of cases (a) and case fatality ratio (b) by age-group and linkage group in England during 2007–11
Ladhani et al. BMC Infectious Diseases  (2015) 15:551 Page 4 of 10
Assessment of the seasonality (Fig. 4a) and dur-
ation of hospital admission for HESonly patients
(Fig. 4b), showed a similar distribution to HES cases
with a negative MRU PCR-test (HES+/MRU-) com-
pared to hospitalised, laboratory-confirmed IMD
(MRU+/HESA39+) cases. In particular, for cases with
admission and discharge dates recorded, both the
HESonly cases (393/1054, 37.3 %) and HES+/MRU-
cases (499/1294, 38.6 %) had a higher proportion of
patients admitted to hospital for ≤48 h compared
with 12.9 % (394/3060) for MRU+/HESA39+ cases.
Moreover, MRU+/HESA39+ cases (840/3935, 21.3 %)
were significantly more likely to have multiple hos-
pital admissions compared with HES+/MRU- (214/
1465, 14.6 %) or HESonly (205/1327, 15.4 %) cases,
and, in <5 year-olds, more likely to have multiple
ICD-10 codes (in addition to A39*) recorded in
HES (67.3 % vs. 57.3 % and 57.7 %, respectively,
P < 0.0001), suggestive of more severe disease/
complications.
Additionally, although CFR among HESonly cases was
3.8 % (51/1327 cases), the age distribution of CFR
showed similarities to the HES+/MRU- cases, with ex-
tremely low CFR in children and then a rapid increase
in CFR among older adults (Fig. 1b). Of these 51 deaths
occurring within 30 days of admission among HESonly
cases, 30 linked to a death registration record with free
text information; of these, only 10 (33 %) recorded men-
ingococcal infection as the cause of death; 12 (40 %)
documented “meningo-encephalitis”, 6 (20 %) had
another pathogen recorded, including GBS (n = 2),
pneumococcal (n = 2) and streptococcal (n = 1) infec-
tions as well as staphylococcal meningitis with ventricu-
litis (n = 1); and two others (7 %) died of complications
following a non-IMD infection. Moreover, analysis of the
interval between hospital admission and death among
fatal cases showed that MRU+/HESA39+ cases were
significantly more likely to die within the first two days
after hospital admission compared to the other two
groups (Fig. 4c).
Fig. 2 Comparison of age distribution between MRU-confirmed cases in England during 2007-11that linked with a HES A39* diagnosis (Fig. 2a)
and those that did not (Fig. 2b). Note the differing Y-axis between the two graphs
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LabBase2 cases
Of the 3278 invasive Neisseria meningitidis records in
LabBase2, almost all (n=3149, (96 %) were also con-
firmed by the MRU. The remaining 129 were then
matched against the HES dataset and 60 were subse-
quently linked, including 43 that linked to a HESonly
case, six to HES+/MRU- and 11 to a HES G00-coded
case. The remaining 69 cases (equivalent to 14 cases/
year), therefore, did not link to HES or MRU cases.
ONS death registrations
Interrogation of deaths registration data identified 3325
cases with an A39* code as a cause of death and/or
“meningo-” and/or “encephalitis” in the free text. Of these,
only 92 additional cases were identified that did not link to
either the MRU-confirmed or HES IMD cases. Manual in-
spection of these records identified 34 non-meningococcal
deaths (e.g. meningo-myelocele, or meningo-encephalitis
cause by another pathogen), four non-infectious deaths in
individuals who had recovered from a previous meningo-
coccal infection, and two deaths with meningo-encephalitis
and no pathogen recorded. Additionally, there were 14
deaths recorded with Waterhouse-Friderichsen Syndrome,
including four associated with a non-meningococcal infec-
tion. Therefore, only 38 deaths were recorded as meningo-
coccal disease over the 5-year period. Two of the 38 death
records also mentioned Waterhouse-Friderichsen syn-
drome. There were, however, ten other death registration
records that also noted Waterhouse-Friderichsen syndrome
– these may or may not have been associated with IMD.
Private laboratory reports
During 2007–11, PHE received 95 private microbiology
laboratory reports of IMD confirmations. Of these, ten
appeared to be cultures submitted as part of a nasopha-
ryngeal carriage study and four others were non-invasive
isolates. Of the remaining 81 cases, 71 (88 %) linked to
the MRU/HES dataset, including MRU+/HESA39+ (35/
71, 49 %) and HESonly (30/71, 42 %). Four additional re-
ports tested PCR-negative at the MRU (HES+/MRU-), but
were recorded as IMD in HES. Of these 4 reports, two
PCR tests were performed more than a week after hospital
admission and two were performed on the day after ad-
mission. Two additional results linked to MRU+/HESA39-
cases. Assuming that the no further linkage of cases was
possible, the private laboratory reports contributed to a
maximum of 44 cases (equivalent to nine cases/year) in
addition to the MRU-confirmed cases over the 5-year
period (30 HESonly, 10 unlinked, 4 HES+/MRU-).
Discussion
The linkage of multiple national data sources has pro-
vided useful insight into the total burden of IMD in
England. The provision of free, national PCR-testing
of clinical samples in addition to species confirmation
and capsular grouping of clinical isolates by the MRU
has not only guided clinical management of patients,
but also improved case ascertainment and complete-
ness of IMD surveillance [6]. LabBase2 and private la-
boratory reports added only a few more cases to the
total number of confirmed IMD reports by the MRU,
Table 2 Summary of the 840 IMD cases diagnosed in England during 2007–2011 that were confirmed by PHE MRU but could
not be linked to a Hospital Episode Statistic (HES) admission matched to an A39* (meningococcal disease) or G00*
(bacterial meningo-encephalitis) diagnosis (MRU+/HESA39- cases)
Outcome of linkage Comment
Linked with a non-specific
Infection-related code (n = 248)
These MRU-confirmed cases did not link with a HES A39* (meningococcal disease) or G00*
(bacterial meningo-encephalitis) diagnosis but had non-specific infection-related codes,
such as rash (n = 75), unspecified fever (n = 73), nausea and vomiting (n = 45), unspecified
septicaemia (n = 31), unspecified viral infection (n = 23), lobar pneumonia (n = 17), unspecified
pneumonia (n = 13) and unspecified viral meningitis (n = 12). Compared to children and adults,
those aged ≥65 years were over-represented among the unlinked cases, possibly because IMD
was less likely to be considered in the differential diagnosis for this age group. The ≥65 year-olds
were also more likely to have a non-meningococcal cause (e.g. pneumococcal pneumonia)
recorded in their discharge diagnosis
NHS numbers available but did not
link to HES admission (n = 210)
These MRU-confirmed cases had NHS numbers but did not link to a HES admission within 30 days
of sample receipt. They were more likely to be infants, toddlers or young adults (15–24 year-olds)
and had the highest case fatality across the age groups (35 %) (Table 3). The most likely explanation
for non-linkage is that these patients died before they could be hospitalised
Another pathogen was recorded
in HES (n = 71)
These MRU-confirmed cases were coded in HES as having another infection, such as group B
streptococcal (n = 14), S. pneumoniae or E. coli infection, or simply Gram-negative septicaemia (n = 12).
Cases without an infection-related
code (n = 26)*
This was the smallest group where the MRU-confirmed case linked to a HES admission that did not
have an infection-related code. Two cases had a HES discharge diagnosis of “diagnosis not known”.
This could be coding error in HES or the patient may have been hospitalised with another illness
within 30 days of MRU-confirmation of IMD
No NHS Number and not linked
to HES admission (n = 285)
These cases followed a similar age-distribution as MRU-confirmed IMD cases, which may suggest
that they are genuine IMD cases but could not be linked to HES because of lack of sufficient identifiers.
IMD invasive meningococcal disease, MRU Meningococcal Reference Unit, HES Hospital Episode Statistic, NHS National Health Service
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Table 3 Number of deaths, cases and case fatality ratio (CFR, %) by age group for the 840 MRU-confirmed cases that did not link to a HES meningococcal disease ICD10 code
(MRU+/HESA39-)
Age group Linked+/Infection-related NHS number+/Unlinked Linked+/Another-pathogen Linked+/Not-infection No NHS number All cases
<1y 5/50 (10.0 %) 20/43 (46.5 %) 0/9 (0.0 %) 1/2 (50.0 %) 7/63 (11.1 %) 33/167 (19.8 %)
1-4y 0/62 (0.0 %) 16/33 (48.5 %) 2/23 (8.7 %) 0/4 (0.0 %) 5/77 (6.5 %) 23/199 (11.6 %)
5-14y 0/33 (0.0 %) 5/16 (31.3 %) 0/5 (0.0 %) 0/3 (0.0 %) 2/34 (5.9 %) 7/91 (7.7 %)
15-24y 5/25 (20.0 %) 10/51 (19.6 %) 1/4 (25.0 %) 0/2 (0.0 %) 3/37 (8.1 %) 19/119 (16.0 %)
25-44y 1/11 (9.1 %) 6/25 (24.0 %) 0/2 (0.0 %) 0/2 (0.0 %) 2/37 (5.4 %) 9/77 (11.7 %)
45-64y 1/21 (4.8 %) 12/25 (48.0 %) 0/6 (0.0 %) 0/4 (0.0 %) 2/18 (11.1 %) 15/74 (20.3 %)
≥65y 5/46 (10.9 %) 5/17 (29.4 %) 3/22 (13.6 %) 2/9 (22.2 %) 1/13 (7.7 %) 16/107 (15.0 %)
Total 17/248 (6.9 %) 74/210 (35.2 %) 6/71 (8.5 %) 3/26 (11.5 %) 22/285 (7.7 %)a 122/840 (14.5 %)a
Cause of death on death
registration record
Bacterial meningitis (2); Viral meningitis
(1); Encephalitis (1); IMD (all others)
IMD (all fatalities) Bacterial Meningitis
(1); IMD (all others)
IMD (all fatalities) Bacterial Meningitis
(1); IMD (all others)
The highest case fatality was observed for the MRU-confirmed cases with NHS numbers that did not link to a HES admission for meningococcal disease (NHS number+/Unlinked). Notably, the ONS death registrations
recorded meningococcal disease as the cause of death for nearly all fatal cases irrespective of the linkage status among these MRU+/HESA39- cases IMD, Invasive meningococcal Disease; MRU, meningococcal reference
unit; HES, Hospital Episode Statistic; NHS, National Health Service












thus confirming two recent publications which
reached the same conclusions [5, 6].
We successfully linked 4275 MRU-confirmed cases
over the five-year period to a hospitalisation record in
HES, where IMD (A39*) or bacterial meningo-
encephalitis (G00*) was recorded. The remaining 840
(16 %) MRU-confirmed cases did not have sufficient iden-
tifiers for successful linkage, had non-specific infection-
related ICD10 codes in HES, or died prior to hospital
admission – either in the Emergency Department or out-
side hospital (e.g. at home).
At the same time, interrogating HES for IMD admis-
sions identified an additional 2792 cases but more than
half matched to an MRU PCR-negative test-result.
Cross-checking these HES+/MRU- cases with LabBase2
and private laboratory reports identified only ten add-
itional cases with positive laboratory confirmation. Dis-
crepancies between the positive LabBase2/private
laboratory testing and negative MRU PCR-tests may be
due to the timing of sample submission or in the sensi-
tivity of the diagnostic tests used. Overall, however, al-
most 1500 patients (equivalent to 300/year) had an IMD
diagnosis in HES with a PCR-negative test by the MRU.
Of the remaining 1327 HES cases that did not match
any MRU-tested samples, only 73 had additional
laboratory-confirmation through LabBase2 or the private
laboratory over the five-year period. This group also had
the lowest proportion of identifiable information for link-
age. It is possible that, if sufficient identifiers had been
available, at least some of MRU-positive cases that did not
link to HES might have linked to these HESonly cases.
This would, however, still not account for >1000 HESonly
cases (equivalent to >200/year) without any laboratory-
confirmation for IMD.
The characteristics of the HESonly cases – age distribu-
tion, seasonality, short duration of in-patient stay (≤48 h
in 40 %) and CFR – resembled HES+/MRU- cases more
than MRU+/HESA39+ cases. In clinical practice, children
(and many adults) often present with non-specific
symptoms and signs such as fever and petechial rash
and these cases usually end up being coded in HES
as IMD because of lack of an alternative, more con-
clusive diagnosis. At the same time, however, some of
these patients will have clinically-diagnosed IMD
cases without laboratory-confirmation (e.g. those who
received antibiotics prior to blood culturing and did
not have a sample submitted for PCR-testing), al-
though it is difficult to estimate the contribution of
such cases to total HESonly cases.
In 1998, when the UK was experiencing a national
MenC outbreak, we had estimated that there were 46 %
more A39+ cases recorded in HES (n = 3316) than con-
firmed by the MRU (n = 2,276) [9]. This was a crude esti-
mate of under-ascertainment because individual-level
data-linkage was not performed. The current study has
demonstrated the additional value of linking multiple
national data sources whilst highlighting the complex-
ities of linking large datasets that were not designed
for integration. A straightforward comparison would
indicate 32 % more HESA39+ (n = 6727) than MRU-
confirmed (n = 5115) cases during 2007–11, which is
lower than 46 % reported in 1998, possibly because of a
higher proportion of cases with laboratory testing and
confirmation [6]. Linkage of individual patient records,
however, showed that a significant proportion of MRU-
confirmed cases were not coded as IMD (A39+) in HES
or died before admission to hospital. At the same time, a
substantial proportion of hospitalised patients with a HES
A39+ discharge code were either identified as PCR-
negative by the MRU or were not laboratory-confirmed.
During 2007–11, therefore, the latter group comprising
1254 HESonly cases would add 25 % more cases to the
Fig. 3 Interval in days between the hospital admission date and the PCR-testing date for MRU-confirmed cases that were coded as meningococcal
disease (A39*) in HES (MRU+/HESA39+) and for HES cases coded as meningococcal disease (A39*) in HES but with a negative PCR-test by the
MRU (HES+/MRU-)
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Fig. 4 Seasonality (a), duration of hospital admission in days (b) and time from hospital admission to death in days (c) for clinically diagnosed
HESonly cases without laboratory confirmation, HES cases with a negative MRU PCR-test (HES+/MRU-) and hospitalised, laboratory-confirmed IMD
(MRU+/HESA39+) cases
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5115 MRU-confirmed cases compared to our previous es-
timate of 46 % excess cases in 1998 [9].
Increasing use of NHS numbers for individual patients
was critical in facilitating successful linkage, as did
access to the patient demographic service (PDS) batch-
testing which provided NHS numbers for cases with
partial identifiers, highlighting the need for a unique
identifier across all data sources for future linkage. For
cases with missing NHS number, linkage success fell
rapidly, making it difficult to ascertain whether the
additional unlinked records are genuinely more cases or
simply unlinked duplicates. Despite the wealth of data
generated, it is clear that linkage of national datasets in
their current format is labour-intensive and not amen-
able to automation, but could be repeated at regular
intervals to monitor trends over time.
Conclusions
Our analysis confirms that the MRU captures nearly all
laboratory-confirmed IMD cases and is, therefore, ideal
for monitoring national trends in near-real time. Linkage
with HES, however, identified an additional 2792 hospi-
talised cases over 5 years with an IMD diagnostic code,
including half that linked to an MRU PCR-negative result;
of the remaining cases, it is difficult to estimate what
proportion were genuine but unconfirmed IMD cases.
Reassuringly, though, these additional HES cases indicate
increased awareness of IMD among clinicians with low
thresholds for hospitalising patients with suspected IMD.
Following the introduction of a broad-spectrum meningo-
coccal vaccine (4CMenB; Bexsero, GSK Biologicals) into
the UK childhood immunisation programme in September
2015, monitoring trends in laboratory-confirmed and
unconfirmed hospitalised IMD cases could provide useful
insight into the true burden of IMD. In the meantime, our
results justify the continued use of MRU data for monitor-
ing IMD epidemiology in England.
Additional file
Additional file 1: Figure S1. Interval between PCR-testing by the
Meningococcal Reference Unit (MRU) and death for the different
subgroups within the cohort of 840 cases that were MRU-confirmed but
did not link to a hospital admission with an A39* (meningococcal disease)
or G00* (bacterial meningo-encephalitis) diagnosis code (MRU+/HESA39-
cases). Nearly all samples for all subgroups were tested on or after the day
of death (i.e. negative interval), suggesting that the patient died without
being admitted to hospital, for example, in the Hospital Emergency
Department or at home. (TIFF 299 kb)
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